30 results about "L858r mutation" patented technology

The invention provides a digital PCR kit for detecting human EGFR gene mutation, the digital PCR kit is characterized in that a plurality of Ex19Del mutations and L858R mutations are simultaneously detected in a same reaction tube digital PCR reaction system, a mutant type is identified at an Ex19Del site by using a plurality of ARMS primers, and a wild type and a mutant type are identified at an L858R site by using a TaqMan fluorescent probe; after PCR amplification, an Ex19Del mutant type, an L858R mutant type and an L858R wild type are detected through the position and intensity of a fluorescence signal, and absolute quantification is directly carried out on the Ex19Del mutant type, the L858R mutant type and the L858R wild type. The kit is high in flux and low in cost, the Ex19Del25 site and the L858R site are combined into one tube for detection, the detection flux is improved, and the cost of reagent consumables is reduced.

Disclosed is a new use of ibrutinib (PCI-32765). In particular, the present invention has found that ibrutinib can treat non-small cell lung cancer carrying EGFR T790M mutations and / or EGFR L858R mutations and / or EGFR delE746_A750 mutations, especially non-small cell lung cancer carrying EGFR L858R and EGFR T790M double mutations.

The invention provides crRNAs for gene mutation of lung cancer-related molecular markers, a detection kit and a detection method thereof. The crRNAs comprise: a crRNA at the EGFR-T790M mutation site:as shown in any one of SEQ ID NO.16-17; a crRNA at the EGFR-L858R mutation site: as shown in any one of SEQ ID NO.18-19; a crRNA at the BRAF gene mutation site: as shown in any one of SEQ ID NO.20-21;a crRNA at the ALK gene mutation site: as shown in any one of SEQ ID NO.22-23; and a crRNA at the ROS1 gene mutation site: as shown in any one of SEQ ID NO.24-25. According to the invention, the 5 crRRNAs related to gene mutation targets of lung cancer-related molecular markers are designed, and the crRNAs are adopted in combination with a CRISPR-cpf1 system to carry out mutation detection. The method of the invention has the characteristics of simplicity, fast speed, high sensitivity and strong specificity.

The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and / or the EGFR L858R mutant gene and / or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and / or ALK F1196M gene and / or EML4-ALK mutant gene and / or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.

The invention provides a primer probe for detecting the EGFR gene L858R mutation, which belongs to the technical field of gene detection. The upstream primer sequence of the L858R mutation is shown in SEQ ID NO: 1; the downstream primer sequence of the L858R mutation is shown in SEQ ID Shown in NO:2; the probe for the L858R mutation is a gold-labeled probe, and its sequence is shown in SEQ ID NO:3. The primer probe used in the present invention has high specificity, accuracy and sensitivity. The invention adopts the RPA amplification technology combined with the lateral flow chromatography test strip to detect the EGFR gene L858R mutation for the first time, and the detection time is short, the operation is simple and the cost is low.

The present invention relates to the technical field of pharmaceutical compositions and relates to a compound containing a pyrimidine ring, an epidermal growth factor receptor (EGFR) inhibitor and application thereof. The compound containing the pyrimidine ring comprises a compound represented by formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof. The EGFR inhibitor comprises the compound containing the pyrimidine ring. The compound can inhibit one or more activating or resistant mutations in EGFR and can be used to prepare drugs for controlling EGFR tyrosine kinase activity or treating EGFR related diseases, such as cancers, diabetes, immune system diseases, neurodegenerative diseases or cardiovascular diseases, and is particularly suitable for preparing drugs for treating non-small cell lung cancer caused by EGFR mutations including sensitive mutations (such as an L858R mutation or an exon 19 deletion mutation) and drug-resistance mutations (such as an EGFR T790M mutation).

The invention discloses an EGFR inhibitor for targetedly treating a cancer and a preparation method and application thereof.The structural formula of the EGFR inhibitor is shown in the formula I.The EGFR inhibitor can be used for preventing and / or treating the cancer such as a human skin caner or a lung cancer.The EGFR inhibitor can selectively inhibit cell lines of EGFR double mutation (EGFRT790M and L858R), and the inhibitory activity to EGFR wild type cells is weak; therefore, the EGFR inhibitor can be used for treating lung cancer patients with EGFRT790M and L858R mutation, and the side effects are fewer, wherein the side effects are caused by inhibiting wild type EGFR, for example, Afatinib.